Clinical Trial

BrECADD Therapy in Stage 2 B-IV Hodgkin Lymphoma

Study acronym: BrECADD
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to further assess the efficacy and tolerability of a regimen of Brentuximab Vedotin, Etoposide, Cyclophosphamide, Doxorubicin, Dacarbazine, and Dexamethasone (BrECADD) in patients with Stage 2 B-IV Hodgkin Lymphoma (HL) with an exploratory objective to assess the clinical utility of Circulating tumor DNA (ctDNA) as a biomarker for minimal residual disease (MRD) and depth of treatment response.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-05-23; most recent amendment 2025-10-30.
Status change: Not Yet Recruiting → Recruiting 2025-07-07
Trial Details
NCT Number NCT07002216
Lead Sponsor University of Miami
Collaborators: Pfizer
Conditions Hodgkin Lymphoma, Advanced Hodgkin Lymphoma
Enrollment 48 participants
Start Date 2025-07-15
Primary Completion 2030-07-15 (estimated)
Study Completion 2030-07-15 (estimated)
Updated on ClinicalTrials.gov 2025-11-03